Vasculogenic mimicry and p53 expression in esophageal squamous cell carcinoma patients of Kazakh ethnicity, the association between vasculogenic mimicry and p53 expression and its influence on prognosis
DOI:
https://doi.org/10.18203/2349-2902.isj20250031Keywords:
Esophageal squamous cell carcinoma, Kazakh ethnicity, Vasculogenic mimicry, p53, Prognosis., Esophageal cancerAbstract
Background: Esophageal cancer (EC), particularly esophageal squamous cell carcinoma (ESCC), is prevalent in Xinjiang, with poor prognosis and notable ethnic differences. Kazakhs are the most affected group. The p53 gene mutation is linked to tumor malignancy and metastasis in EC, though its prognostic role is debated. Vasculogenic mimicry (VM), a non-classical angiogenesis model, contributes to tumor progression and correlates with poor outcomes. This study investigates the relationship between VM and p53 expression in Kazakh ESCC patients to understand their clinical and prognostic significance.
Methods: This retrospective cross-sectional study analyzed 76 Kazakh ESCC patients to assess VM and p53 expression using histological staining and immunohistochemistry between December 2010 and November 2015. Clinicopathological features, survival outcomes, and the correlation between VM and p53 were evaluated using Spearman correlation, Kaplan-Meier curves, and Cox regression analysis. Ethical approval and informed consent were obtained.
Results: VM was identified in 42.1% of Kazakh ESCC tissues, associated with advanced stages, lymph node metastasis, and poor differentiation (p<0.001). Kaplan-Meier analysis revealed that VM presence significantly reduced survival time (p<0.05). Mutant p53 expression correlated with tumor differentiation but not survival. Spearman analysis showed a significant association between VM and p53 positivity. VM and lymph node metastasis were independent prognostic factors, underscoring VM’s critical role in ESCC progression.
Conclusion: Vasculogenic mimicry (VM) is a marker of poor prognosis in Kazakh EC, correlating with advanced stages and higher metastasis rates. The association between VM and p53 mutations highlights their combined role in tumor progression and potential as therapeutic targets.
Metrics
References
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. DOI: https://doi.org/10.3322/caac.21492
Kamangar F, Dores GM, Anderson WF. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol. 2006;24(14):2137-50. DOI: https://doi.org/10.1200/JCO.2005.05.2308
Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9-29. DOI: https://doi.org/10.3322/caac.21208
Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, et al. Cancer statistics in China, 2015. CA Cancer J Clin. 2016;66(2):115-32. DOI: https://doi.org/10.3322/caac.21338
Zeng H, Zheng R, Zhang S, Zuo T, Xia C, Zou X, et al. Esophageal cancer statistics in China, 2011: Estimates based on 177 cancer registries. Thorac Cancer. 2016;7(2):232-7. DOI: https://doi.org/10.1111/1759-7714.12322
Awut I, Niyaz M, Huizhong X, Biekemitoufu H, Yan HZ, Zhu Z, et al. Genetic diagnosis of patients with esophageal cancer using FISH. Oncol Lett. 2010;1(5):809-13. DOI: https://doi.org/10.3892/ol_00000142
Arnal MJD, Arenas ÁF, Arbeloa ÁL. Esophageal cancer: Risk factors, screening and endoscopic treatment in Western and Eastern countries. World J Gastroenterol. 2015;21:7933-43. DOI: https://doi.org/10.3748/wjg.v21.i26.7933
Hassanipour S, Mohammadian-Hafshejani A, Ghoncheh M, Salehiniya H. The incidence and mortality of esophageal cancer and its relationship with development in the world. Biomed Res Therapy. 2017;4(9):1607. DOI: https://doi.org/10.15419/bmrat.v4i9.368
Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994;54(18):4855-78.
Song Y, Li L, Ou Y, Gao Z, Li E, Li X, et al. Identification of genomic alterations in oesophageal squamous cell cancer. Nature. 2014;508(7498):91-5. DOI: https://doi.org/10.1038/nature13176
Huang K, Chen L, Zhang J, Wu Z, Lan L, Wang L, et al. Elevated p53 expression levels correlate with tumor progression and poor prognosis in patients exhibiting esophageal squamous cell carcinoma. Oncol Lett. 2014;8(4):1441-6. DOI: https://doi.org/10.3892/ol.2014.2343
Zhao Z, Wang P, Gao Y, He J. The high expression instead of mutation of p53 is predictive of overall survival in patients with esophageal squamous-cell carcinoma: a meta-analysis. Cancer Med. 2017;6(1):54-66. DOI: https://doi.org/10.1002/cam4.945
Muller PAJ, Vousden KH. Mutant p53 in cancer: New functions and therapeutic opportunities. Cancer Cell. Cell Press. 2014;25:304-17. DOI: https://doi.org/10.1016/j.ccr.2014.01.021
Dunleavey JM, Dudley AC. Vascular mimicry: Concepts and implications for anti-angiogenic therapy. Vol. 1, Current Angiogenesis. Bentham Science Publishers. 2012;133-8. DOI: https://doi.org/10.2174/2211552811201020133
Kirschmann DA, Seftor EA, Hardy KM, Seftor REB, Hendrix MJC. Molecular pathways: Vasculogenic mimicry in tumor cells: Diagnostic and therapeutic implications. Clin Cancer Res. 2012;18:2726-32. DOI: https://doi.org/10.1158/1078-0432.CCR-11-3237
Liu W, Lv C, Zhang B, Zhou Q, Cao Z. MicroRNA-27b functions as a new inhibitor of ovarian cancer-mediated vasculogenic mimicry through suppression of VE-cadherin expression. RNA. 2017;23(7):1019-27. DOI: https://doi.org/10.1261/rna.059592.116
Yang WY, Tan ZF, Dong DW, Ding Y, Meng H, Zhao Y, et al. Association of aquaporin-1 with tumor migration, invasion and vasculogenic mimicry in glioblastoma multiforme. Mol Med Rep. 2018;17(2):3206-11. DOI: https://doi.org/10.3892/mmr.2017.8265
Williamson SC, Metcalf RL, Trapani F, Mohan S, Antonello J, Abbott B, et al. Vasculogenic mimicry in small cell lung cancer. Nat Commun. 2016;9:7. DOI: https://doi.org/10.1038/ncomms13322
Chen Q, Lin W, Yin Z, Zou Y, Liang S, Ruan S, et al. Melittin Inhibits Hypoxia-Induced Vasculogenic Mimicry Formation and Epithelial-Mesenchymal Transition through Suppression of HIF-1α/Akt Pathway in Liver Cancer. Evid Based Complement Alternat Med. 2019;2019:9602935. DOI: https://doi.org/10.1155/2019/9602935
Luan YY, Liu ZM, Zhong JY, Yao RY, Yu HS. Effect of grape seed proanthocyanidins on tumor vasculogenic mimicry in human triple-negative breast cancer cells. Asian Pac J Cancer Prev. 2015;16(2):531-5. DOI: https://doi.org/10.7314/APJCP.2015.16.2.531
Spiliopoulos K, Peschos D, Batistatou A, Ntountas I, Agnantis N, Kitsos G. Vasculogenic mimicry: lessons from melanocytic tumors. In Vivo. 2015;29(3):309-17.
Cheng TH, Hsu PK, Li AFY, Hung IC, Huang MH, Hsu HS. Correlation of p53, MDM2 and p14ARF protein expression in human esophageal squamous cell carcinoma. J Cancer Res Clin Oncol. 2009;135(11):1577-82. DOI: https://doi.org/10.1007/s00432-009-0605-5
Yasuda M, Kuwano H, Watanabe M, Toh Y, Ohno S, Sugimachi K. p53 Expression in squamous dysplasia associated with carcinoma of the oesophagus: Evidence for field carcinogenesis. Br J Cancer. 2000;83(8):1033-8. DOI: https://doi.org/10.1054/bjoc.2000.1443
Wang L, Yu X, Li J, Zhang Z, Hou J, Li F. Prognostic significance of p53 expression in patients with esophageal cancer: A meta-analysis. BMC Cancer. 2016;16(1). DOI: https://doi.org/10.1186/s12885-016-2427-6
Izawa Y, Kashii-Magaribuchi K, Yoshida K, Nosaka M, Tsuji N, Yamamoto A, et al. Stem-like human breast cancer cells initiate vasculogenic mimicry on matrigel. Acta Histochem Cytochem. 2018;51(6):173-83. DOI: https://doi.org/10.1267/ahc.18041
Downloads
Published
How to Cite
Issue
Section
